BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's ...

The Bioindustry Award, now marking its 9th year, recognizes achievements that have significantly contributed to the development of the bioindustry or are expected to contribute to its future growth.

Dementia is a condition that affects memory, thinking, and behavior, and it tends to get worse over time. While there is ...

HEALTH campaigners fear the country is sleepwalking into a dementia care crisis. Alzheimer Scotland bosses have launched a ...

Andrew Frank and Katherine C. Pearson, QUOI MediaAlzheimer’s disease is an insidious and relentless loss of memory and thinking, accompanied by a gradual ...

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization ...

Cognition Therapeutics surges 35% after a positive FDA meeting for Alzheimer’s drug zervimesine. Read more here.

The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

Japanese authorities are putting Eisai (TYO: 4523) under pressure to reconsider the price of its Alzheimer’s disease therapy ...

.

Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a reduced risk of adverse reactions that may have held back its uptake in the ...